The term “therapy” always is welcome when dealing with neuromuscular diseases, and I am pleased to report that the literature this quarter contains articles on promising treatments for muscle diseases, including some very exciting work on gene therapy. Over the past several years, genetics have assumed increasing importance in the neuromuscular literature, and this is apparent not only from the gene therapy article but also from articles on the genetics of so-called “sporadic” amyotrophic lateral sclerosis. There are also important studies reminding us that neuromuscular diseases have manifestations beyond the nervous system. Studies on statins described below will undoubtedly lead clinicians to reassess the frequently asked questions about the use of these agents in patients with neuromuscular disorders. Finally, peripheral neuropathies and some natural history and classification studies round out this issue's review.